CHRS Stock Overview
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States.
Coherus BioSciences, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$13.39|
|52 Week High||US$19.32|
|52 Week Low||US$5.60|
|1 Month Change||68.01%|
|3 Month Change||79.73%|
|1 Year Change||-8.73%|
|3 Year Change||-33.28%|
|5 Year Change||-2.97%|
|Change since IPO||6.19%|
Recent News & Updates
Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli
The U.S. Food and Drug Administration (FDA) approved Coherus BioSciences' (NASDAQ:CHRS) Cimerli, a biosimilar interchangeable with Roche's (OTCQX:RHHBY) (OTCQX:RHHBF) eye disorder drug Lucentis, for all five indications. "CIMERLI, the only biosimilar product interchangeable with Lucentis across all five indications, will provide both greater treatment access and choice for patients, payors and providers in the U.S. retinal disease community," said Coherus Chief Commercial Officer Paul Reider. The company said the uses of Cimerli (ranibizumab-eqrn) include: Neovascular (wet) Age-Related Macular Degeneration, Macular Edema following Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy, and Myopic Choroidal Neovascularization. Coherus noted that Cimerli has 1 year of interchangeability exclusivity. Coherus said commercial availability of Cimerli (ranibizumab-eqrn), in both 0.3 mg and 0.5 mg dosages, is planned for early October 2022. The company noted that the approval was backed by data from clinical programs, including the COLUMBUS-AMD study. CHRS +13.67% to $11.39 premarket Aug. 3.
Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer
The U.S. Food and Drug Administration (FDA) accepted for review Coherus BioSciences (NASDAQ:CHRS) and Shanghai Junshi Biosciences' (OTCPK:SHJBF) resubmitted application seeking approval of toripalimab to treat a rare type of head and neck cancer. The companies' biologics license application (BLA) is seeking approval of toripalimab in combination with gemcitabine and cisplatin as first-line therapy for patients with advanced recurrent or metastatic nasopharyngeal carcinoma (NPC) and for toripalimab monotherapy as a second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy. NPC originates in the nasopharynx, which is located behind the nose and above the back of the throat. The FDA is expected to take a decision on the BLA by Dec. 23. "We collaborated closely with our partner, Junshi Biosciences, to complete the quality process changes requested by the FDA and facilitate the rapid resubmission of the toripalimab BLA,” said Theresa LaVallee, chief development officer, Coherus (CHRS). Coherus (CHRS) plans to launch toripalimab in the U.S. in Q1 2023, if approved.
|CHRS||US Biotechs||US Market|
Return vs Industry: CHRS exceeded the US Biotechs industry which returned -19.6% over the past year.
Return vs Market: CHRS matched the US Market which returned -9.6% over the past year.
|CHRS Average Weekly Movement||12.0%|
|Biotechs Industry Average Movement||12.5%|
|Market Average Movement||7.6%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: CHRS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: CHRS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis.
Coherus BioSciences, Inc. Fundamentals Summary
|CHRS fundamental statistics|
Is CHRS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CHRS income statement (TTM)|
|Cost of Revenue||US$72.72m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.97|
|Net Profit Margin||-83.47%|
How did CHRS perform over the long term?See historical performance and comparison